Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral SolutionGlobeNewsWire • 02/25/26
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11thGlobeNewsWire • 02/20/26
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4thGlobeNewsWire • 11/24/25
Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18thGlobeNewsWire • 11/12/25
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research • 11/06/25
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025GlobeNewsWire • 10/23/25
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare ConferenceGlobeNewsWire • 08/20/25
Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With OptionsSeeking Alpha • 08/08/25
Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/07/25
Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 07/31/25
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025GlobeNewsWire • 07/28/25
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)GlobeNewsWire • 07/08/25
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® IndexesGlobeNewsWire • 06/27/25
Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More UpsideSeeking Alpha • 06/06/25
Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 06/02/25
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 RevenueBenzinga • 05/29/25